Search

Author/Creator Liu, J.

21. 197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC). (December 2022)

Authors:
Moore, K.N.; Bouberhan, S.; Hamilton, E.; Liu, J.; O'Cearbhaill, R.E.; O'Malley, D.; Papadimitriou, K.; Schröder, D.; Van Nieuwenhuysen, E.; Yoo, S-Y.; Peterman, M.; Goncalves, P.; Schmidt, T.; Zhu, M.; Lowy, I.; Uldrick, T.; Miller, E.A.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

29. 2820 Association of p16 status and feeding tube use in patients with locoregionally advanced squamous cell cancer of the head and neck treated with radiotherapy +/- cetuximab in a phase III study. (September 2015)

Authors:
Bonner, J.A.; Giralt, J.; Harari, P.M.; Baselga, J.; Spencer, S.; Bell, D.; Liu, J.; Schulten, J.; Ang, K.K.; Rosenthal, D.I.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S564
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

30. 286 THE NOVEL FC-ENGINEERED CD33 ANTIBODY BI 836858 IMPROVES HEMATOPOIESIS BY PROTECTING HSC/HPC FROM ROS-MEDIATED DNA DAMAGE IN MDS. Issue 1 (April 2015)

Authors:
Eksioglu, E.A.; Chen, X.; Heider, K.H.; Rueter, B.; Burnette, A.; Wei, M.; McGraw, K.; Liu, J.; Basiorka, A.; Patel, P.; Lancet, J.; Komrokji, R.; List, A.; Wei, S.
Journal:
Leukemia research
Issue:
Volume 39:Issue 1(2015:Jan.)
Page Start:
S142
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗